Latest Mapatumumab Stories
Calando Pharmaceuticals, a majority-owned subsidiary of Arrowhead Research, has completed the IT-101 Phase I clinical study conducted at City of Hope in Duarte, California. The company expects the entire study data to be published in early 2009.
SOUTH SAN FRANCISCO, Oct.
AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, announced today that its lead product, ANG1005, is safe and well tolerated in patients with brain cancer treated to date.
Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of its Phase II trial evaluating a combination regimen of bavituximab with carboplatin and paclitaxel in patients with non-small cell lung cancer.
TUSTIN, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc.
Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that four posters containing data on GSK-923295, an inhibitor of centromere-associated protein E (CENP-E) and data on SB-743921, an inhibitor of kinesin spindle protein (KSP) are scheduled to be presented at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held from October 21-24, 2008 at the Geneva Palexpo, Geneva, Switzerland.
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) announced today the completion of enrollment as per protocol in the Phase 2 clinical trial of sapacitabine, the Company's oral nucleoside analogue, in elderly patients with acute myeloid leukemia (AML).
Peregrine Pharmaceuticals, a clinical stage biopharmaceutical company, has completed enrollment in the first stage of a Phase II trial of bavituximab in combination with chemotherapy in patients with advanced breast cancer. This is Peregrine's second Phase II study for the treatment of breast cancer.
TransMolecular, a biotechnology company focused on targeted therapies for cancer, has initiated dosing in a Phase I/II trial of 131I-TM601 delivered intravenously for the treatment of adult patients with recurrent malignant glioma.
S BIO, a biotech company, has initiated multi-center Phase I clinical trials of SB1518, a potent and orally-active JAK2 inhibitor, in patients with leukemia and certain types of lymphoma.
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.